Anti-obesity drug development
The DOI matches its Crossref record; 14 of the 14 references it cites were found in a registry or an index.
Abstract
Obesity accelerates morbidity and mortality and has been described by the World Health Organization (WHO) as an epidemic in many industrialised nations [101,102]. Diet, exercise and lifestyle recommendations have proven to be mostly ineffective in adequately preventing or treating the progression of this public health disease. Existing drug treatment is limited by the scarce number of safe and well-tolerated drugs with proven long-term efficacy in maintaining weight loss. Numerous anti-obesity drugs in development have promise. Yet, despite that obesity is the single most common nutritional problem in many developed nations and despite the devastating health consequences of this unchecked epidemic, investigational anti-obesity drugs face unique and significant challenges due to past and current experiences with anti-obesity drugs. It is anticipated that new anti-obesity drugs for this serious, multifaceted metabolic disease will become as safe and effective and as medically accepted as the treatment of other metabolic disorders such as hypertension, dyslipidaemia or Type 2 diabetes mellitus. This may be particularly important, given that these metabolic disorders may be largely due to or exacerbated by obesity itself.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Gut hormone PYY3-36 physiologically inhibits food intake
Batterham, R. L., Cowley, M. A., Small, C. J., Herzog, H., Cohen, M. A., Dakin, C. L., Wren, A. M., Brynes, A. E., Low, M. J., Ghatei, M. A., et al. (2002) · Nature · doi:10.1038/nature00887 · Cited by 2,351
A transgenic model of visceral obesity and the metabolic syndrome
Masuzaki, H., Paterson, J., Shinyama, H., Morton, N. M., Mullins, J. J., Seckl, J. R., & Flier, J. S. (2001) · Science · doi:10.1126/science.1066285 · Cited by 1,766 · cited 1×
“Further anti-obesity drugs in development may target adipocyte 11 beta hydroxysteroid dehydrogenase Type 1 activity, which may be a molecular cause of visceral obesity, as well as the metabolic syndrome [66].”
BackgroundHeymsfield, S. B., Greenberg, A. S., Fujioka, K., Dixon, R. M., Kushner, R., Hunt, T., Lubina, J. A., Patane, J., Self, B., Hunt, P., et al. (1999) · JAMA · doi:10.1001/jama.282.16.1568 · Cited by 1,422
Singh, J. P., Evans, J. C., Levy, D., Larson, M. G., Freed, L. A., Fuller, D. L., Lehman, B., & Benjamin, E. J. (1999) · The American Journal of Cardiology · doi:10.1016/s0002-9149(98)01064-9 · Cited by 1,339 · cited 1×
“Aortic regurgitation was considerably lower [75].”
Zander, M., Madsbad, S., Madsen, J. L., & Holst, J. J. (2002) · The Lancet · doi:10.1016/s0140-6736(02)07952-7 · Cited by 1,297 · cited 1×
“GLP-1 may also delay gastric emptying [52,53], but does not affect lipolysis [54].”
BackgroundSjöström, L., Rissanen, A., Andersen, T., Boldrin, M., Golay, A., Koppeschaar, H. P., & Krempf, M. (1998) · The Lancet · doi:10.1016/s0140-6736(97)11509-4 · Cited by 1,237
Davidson, M. H., Hauptman, J., DiGirolamo, M., Foreyt, J. P., Halsted, C. H., Heber, D., Heimburger, D. C., Lucas, C. P., Robbins, D. C., Chung, J., et al. (1999) · JAMA · doi:10.1001/jama.281.3.235 · Cited by 947 · cited 1×
“Lipid blood levels improve with orlistat treatment and this benefit may exceed what would be expected based upon weight loss alone [22-24].”
BackgroundEffect of sibutramine on weight maintenance after weight loss: a randomised trial
James, W. P. T., Astrup, A., Finer, N., Hilsted, J., Kopelman, P., Rössner, S., Saris, W. H. M., & Gaal, L. F. V. (2000) · The Lancet · doi:10.1016/s0140-6736(00)03491-7 · Cited by 817
Rothman, R. B., Baumann, M. H., Savage, J. E., Rauser, L., McBride, A., Hufeisen, S. J., & Roth, B. L. (2000) · Circulation · doi:10.1161/01.cir.102.23.2836 · Cited by 722 · cited 1×
“However, these drugs were withdrawn from the market due to onset of heart valve abnormalities thought possibly to be related to the nonselectivity of 5HT receptors agonist activity, particularly in those tissues with peripheral 5-HT2b receptors [34,35].”
BackgroundPasquali, R., Gambineri, A., Biscotti, D., Vicennati, V., Gagliardi, L., Colitta, D., Fiorini, S., Cognigni, G. E., Filicori, M., & Morselli-Labate, A. M. (2000) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.85.8.6738 · Cited by 635 · cited 1×
“Treatment with metformin has also been shown to correct many of the other metabolic abnormalities associated with obesity [57].”
BackgroundRössner, S., Sjöström, L., Noack, R., Meinders, A. E., Noseda, G., & Study, O. B. O. T. E. O. O. (2000) · Obesity Research · doi:10.1038/oby.2000.8 · Cited by 476 · cited 1×
“Weight loss with orlistat treatment improves glucose tolerance, prevents the development of Type 2 diabetes mellitus in obese patients [25], improves glucose blood levels in patient with Type 2 diabetes mellitus [26] and improves high blood pressure [27].”
BackgroundWeekly Subcutaneous Pegylated Recombinant Native Human Leptin (PEG-OB) Administration in Obese Men
Hukshorn, C. J., Saris, W. H. M., Westerterp-Plantenga, M. S., Farid, A. R., Smith, F. J., & Campfield, L. A. (2000) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.85.11.6955 · Cited by 220
Does obesity contribute as much to morbidity as poverty or smoking?
Sturm, R. (2001) · Public Health · doi:10.1016/s0033-3506(01)00449-8 · Cited by 194
Effect of triiodothyronine on mitochondrial energy coupling in human skeletal muscle
Lebon, V., Dufour, S., Petersen, K. F., Ren, J., Jucker, B. M., Slezak, L. A., Cline, G. W., Rothman, D. L., & Shulman, G. I. (2001) · Journal of Clinical Investigation · doi:10.1172/jci200111775 · Cited by 174
Cited by
Bays, H. E., Chapman, R. H., Grandy, S., & the SHIELD Investigators’ Group (2007) · International Journal of Clinical Practice · doi:10.1111/j.1742-1241.2007.01336.x · Cited by 510
Self-citationGhrelin in the regulation of body weight and metabolism
Castañeda, T. R., Tong, J., Datta, R., Culler, M., & Tschöp, M. H. (2010) · Frontiers in Neuroendocrinology · doi:10.1016/j.yfrne.2009.10.008 · Cited by 352
Serotonergic Drugs: Effects on Appetite Expression and Use for the Treatment??of Obesity
Halford, J. C. G., Harrold, J. A., Boyland, E. J., Lawton, C. L., & Blundell, J. E. (2007) · Drugs · doi:10.2165/00003495-200767010-00004 · Cited by 307
Current and investigational antiobesity agents and obesity therapeutic treatment targets
Bays, H. E. (2004) · Obesity Research · doi:10.1038/oby.2004.151 · Cited by 228
Self-citationBays, H. E. (2012) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2012.08.029 · Cited by 73
Self-citation
Metadata
- Authors
- Bays, H., & Dujovne, C.
- Venue
- Expert Opinion on Investigational Drugs
- Publisher
- Informa UK Limited
- Published
- 2002-09
- Volume
- 11
- Issue
- 9
- Pages
- 1189-1204
- ISSN
- 1354-3784 (ISSN-L)
- 1744-7658
- OpenAlex
- W2023709599
- Cited by
- 41
- References
- 14
- FWCI
- 1.49
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.